Literature DB >> 17050935

Superficial basal cell carcinoma on face treated with 5% imiquimod cream.

Amit Kumar Malhotra1, Arika Bansal, Asit R Mridha, Binod K Khaitan, Kaushal K Verma.   

Abstract

Imiquimod, an immune response modifier, is known to possess both anti-viral and anti-tumor effect. We report our experience of treating a large superficial spreading basal cell carcinoma with 5% imiquimod cream. A 65-year-old male had an asymptomatic, hyperpigmented, slowly progressive, indurated, 3 x 4 cm plaque on the left cheek for two months. Biopsy from the lesion showed features of basal cell carcinoma. The patient was treated with imiquimod 5% cream, topically three times a week for six months with complete resolution of the lesion and without any side-effects. There was no clinical or histological recurrence after three months of stopping the treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050935     DOI: 10.4103/0378-6323.27757

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  2 in total

1.  Periungual Basal cell carcinoma: a case report with review of literature.

Authors:  Debabrata Bandyopadhyay; Sumit Sen
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

2.  Successful Treatment of Giant Basal Cell Carcinoma with Topical Imiquimod 5% Cream with Long Term Follow-up.

Authors:  M Chun-Guang; L Qi-Man; Zh Yu-Yun; Ch Li-Hua; Tiffany Cheng; H Jian-De
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.